Ubs Oconnor LLC Syndax Pharmaceuticals Inc Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 50,000 shares of SNDX stock, worth $654,000. This represents 0.07% of its overall portfolio holdings.
Number of Shares
50,000Holding current value
$654,000% of portfolio
0.07%Shares
4 transactions
Others Institutions Holding SNDX
# of Institutions
230Shares Held
90MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$103 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$76.4 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$65.2 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$63.9 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$53.7 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $740M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...